These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20375795)

  • 1. Secondary surgery in patients with serous low malignant potential ovarian tumors with peritoneal implants.
    Kane A; Uzan C; Rey A; Gouy S; Duvillard P; Morice P
    Int J Gynecol Cancer; 2010 Apr; 20(3):346-52. PubMed ID: 20375795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
    da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
    Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
    Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
    Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian serous borderline tumors with invasive peritoneal implants.
    Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
    Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of patients with advanced-stage borderline ovarian tumors after a first peritoneal noninvasive recurrence: impact on further management.
    Uzan C; Zanini-Grandon AS; Bentivegna E; Gouy S; Leary A; Duvillard P; Morice P
    Int J Gynecol Cancer; 2015 Jun; 25(5):830-6. PubMed ID: 25828751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern.
    Laurent I; Uzan C; Gouy S; Pautier P; Duvillard P; Morice P
    Ann Surg Oncol; 2008 Dec; 15(12):3561-6. PubMed ID: 18820973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
    Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
    Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
    Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary psammocarcinoma of the ovary or peritoneum.
    Poujade O; Uzan C; Gouy S; Pautier P; Duvillard P; Morice P
    Int J Gynecol Cancer; 2009 Jul; 19(5):844-6. PubMed ID: 19574771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants.
    Deffieux X; Morice P; Camatte S; Fourchotte V; Duvillard P; Castaigne D
    Gynecol Oncol; 2005 Apr; 97(1):84-9. PubMed ID: 15790442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.
    Chi DS; Barlin JN; Ramirez PT; Levenback CF; Mironov S; Sarasohn DM; Iyer RB; Dao F; Hricak H; Barakat RR
    Int J Gynecol Cancer; 2010 Apr; 20(3):353-7. PubMed ID: 20375796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serous borderline tumors of the ovary with noninvasive peritoneal implants.
    Gershenson DM; Silva EG; Tortolero-Luna G; Levenback C; Morris M; Tornos C
    Cancer; 1998 Nov; 83(10):2157-63. PubMed ID: 9827720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-risk borderline ovarian tumors: analysis of clinicopathological features and prognostic impact of different follow-up strategies.
    Lorusso D; Ratti M; Ditto A; Raspagliesi F
    Oncology; 2014; 87(3):183-92. PubMed ID: 25033912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of cytoreductive surgery for advanced and recurrent ovarian neoplasms and papillary serous carcinomas of the peritoneum].
    Ivanov S; Ivanov S
    Akush Ginekol (Sofiia); 2004; 43(5):36-8. PubMed ID: 15518283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
    Kennedy AW; Hart WR
    Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.
    Maria S; Faron M; Maulard A; Pautier P; Leary A; Chargari C; Genestie C; Gouy S; Morice P
    Gynecol Oncol; 2020 Sep; 158(3):659-665. PubMed ID: 32571680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential.
    Crispens MA; Bodurka D; Deavers M; Lu K; Silva EG; Gershenson DM
    Obstet Gynecol; 2002 Jan; 99(1):3-10. PubMed ID: 11777502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Peregrin I; Mendizabal E; Ortiz-Quintana L
    Int J Gynecol Cancer; 2015 Jan; 25(1):49-54. PubMed ID: 25405578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.